Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine

J Headache Pain. 2010 Oct;11(5):431-5. doi: 10.1007/s10194-010-0241-0. Epub 2010 Jul 22.

Abstract

Migraine is a common type of headache and its most severe attacks are usually treated with triptans, the efficacy of which is extremely variable. Several SNPs in genes involved in metabolism and target mechanisms of triptans have been described. To define an association between genetic profile and triptan response, we classified a migrainous population on the basis of triptan response and characterized it for polymorphisms in the genes coding for monoamine oxidase A, G protein β3 and the cytochrome CYP1A2. Analysis of the association between genotypic and allelic frequencies of the analyzed SNPs and the grade of response to triptan administration showed a significant correlation for MAOA uVNTR polymorphism. Further stratification of patients in abuser and non-abuser groups revealed a significant association with triptan overuse and, within the abusers, with drug response to the CYP1A2*1F variant.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Chronic Disease
  • Cytochrome P-450 CYP1A2 / genetics*
  • Female
  • Gene Frequency
  • Genotype
  • Heterotrimeric GTP-Binding Proteins / genetics
  • Humans
  • Male
  • Middle Aged
  • Migraine Disorders / drug therapy*
  • Migraine Disorders / genetics*
  • Minisatellite Repeats / genetics*
  • Monoamine Oxidase / genetics*
  • Pharmacogenetics
  • Polymorphism, Single Nucleotide / genetics
  • Substance-Related Disorders / etiology
  • Substance-Related Disorders / genetics
  • Tryptamines / therapeutic use*

Substances

  • G-protein beta3 subunit
  • Tryptamines
  • Cytochrome P-450 CYP1A2
  • Monoamine Oxidase
  • Heterotrimeric GTP-Binding Proteins